drugset
drugset / Trial / NCT01184976

Study Of VGX-3400, H5N1 Avian Flu Virus Plasmid DNA With Electroporation Device In Healthy Adult Males

NCT01184976 ↗

Phase 1 Completed 30 enrolled GeneOne Life Science, Inc. Inovio Pharmaceuticals · collab
Non-randomizedParallel-groupOpen-labelPrevention

Summary

Research Hypothesis: VGX-3400 (DNA plasmids encoding the hemagglutinin (HA), neuraminidase (NA), and M2e-NP antigen of the H5N1 avian influenza virus) administered to healthy adult males by IM injection followed by EP will be generally well tolerated and immunogenic.

Timeline

Start
2010-08
Primary completion
2012-04
Completion
2012-04

Drugs

EvaluationDrugModalityDoseRoute
Subject VGX-3400 Vaccine 0.6 mg Intramuscular
Subject VGX-3400 Vaccine 2 mg Intramuscular
Subject VGX-3400 Vaccine 6 mg Intramuscular

Indications

No indication recorded.